“Non-Cystic Fibrosis Bronchiectasis Market” report has been added to DelveInsight
The Non-Cystic Fibrosis Bronchiectasis Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non-Cystic Fibrosis Bronchiectasis Market
Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market
Non-Cystic Fibrosis Bronchiectasis Disease Overview
Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.
Non-Cystic Fibrosis Bronchiectasis Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Non-Cystic Fibrosis Bronchiectasis Key Players
- Aradigm Corporation
- Zambon
- Novartis Pharmaceuticals
- Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis Drugs
- Ciprofloxacin dispersion for inhalation
- Colistimethate sodium
- Tobramycin inhalation powder
- INS1007
Non-Cystic Fibrosis Bronchiectasis Prevalence
Prevalence of NCFB is reported to be higher in females. The prevalence of NCFB vary among populations, but studies report an overall prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals.
Non-Cystic Fibrosis Bronchiectasis Market Report
NCFB results in irreversible changes in the bronchial walls which may occur due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified. Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum.
Non-Cystic Fibrosis Bronchiectasis Market Outlook
When a specific disorder is found to cause bronchiectasis, disease management is then primarily directed at the underlying cause. While in case of Non‐Cystic Fibrosis Bronchiectasis management is aimed at preventing disease progression and improving quality of life by reducing symptoms and exacerbations.
Treatment is based on breaking the vicious cycle using mucoactive treatments and airway clearance techniques (ACTs) to enhance mucus clearance, inhaled or oral antibiotic therapy to reduce chronic bronchial infection, anti-inflammatory therapies to decrease associated inflammation, bronchodilator therapy, surgery, and pulmonary rehabilitation. Many treatment options for non-CF bronchiectasis are derived from the treatment regimens developed for cystic fibrosis.
Non-Cystic Fibrosis Bronchiectasis Physiotherapy
Most patients with bronchiectasis, especially those with excessive secretions, are offered physiotherapy. Forced expiratory manoeuvres, as well as hand-held devices generating positive expiratory pressure (‘pep’ devices), such as Flutter or Acapella, are used for optimal sputum clearance.
Non-Cystic Fibrosis Bronchiectasis Market Report Scope
- The report covers the descriptive overview of Non-cystic fibrosis bronchiectasis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
- Comprehensive insight has been provided into the Non-cystic fibrosis bronchiectasis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Non-cystic fibrosis bronchiectasis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Non-cystic fibrosis bronchiectasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non-cystic fibrosis bronchiectasis market
Download free sample copy here- https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market
Following is the TOC Market Report
1. Key Insights
2. Executive Summary of Non-Cystic Fibrosis Bronchiectasis (NCFB)
3. Competitive Intelligence Analysis for Non-Cystic Fibrosis Bronchiectasis (NCFB)
4. Non-Cystic Fibrosis Bronchiectasis (NCFB): Market Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis (NCFB): Disease Background and Overview
6. Patient Journey
7. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment
11. Marketed Products
12. Emerging Therapies
13. Non-Cystic Fibrosis Bronchiectasis (NCFB): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Non-Cystic Fibrosis Bronchiectasis (NCFB)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Non-cystic fibrosis bronchiectasis market
- To understand the future market competition in the Non-cystic fibrosis bronchiectasis market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Non-cystic fibrosis bronchiectasis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Non-cystic fibrosis bronchiectasis market
- To understand the future market competition in the Non-cystic fibrosis bronchiectasis market
Related Reports
Non-Cystic Fibrosis Bronchiectasis Epidemiology
DelveInsight’s Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology
Non-Cystic Fibrosis Bronchiectasis Pipeline
Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/